{"url_path":"/sec/imvt/10-k/2026/item-11","section_key":"item-11","section_title":"Item 11 Executive Compensation","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1764013/0001764013-26-000064-index.html","accession_number":"0001764013-26-000064","cik":"0001764013","ticker":"IMVT","issuer_name":"Immunovant, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1764013/0001764013-26-000064-index.html","primary_entity_key":"0001764013","primary_entity_name":"Immunovant, Inc."},"word_count":41,"has_tables":true,"body_markdown":"Item 11. Executive Compensation\n\nThe information required by this item will be contained in our 2026 Proxy Statement under the captions “Information Regarding the Board of Directors and Corporate Governance,” “Executive Compensation” and “Director Compensation” and is incorporated herein by reference."}